Aptose Biosciences Inc   (APTO)
Other Ticker:  
Price: $0.7420 $-0.02 -2.368%
Day's High: $0.808 Week Perf: -14.71 %
Day's Low: $ 0.73 30 Day Perf: -34.34 %
Volume (M): 42 52 Wk High: $ 5.58
Volume (M$): $ 31 52 Wk Avg: $2.47
Open: $0.80 52 Wk Low: $0.73

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Aptose Biosciences Inc
Aptose Biosciences Inc is a Canadian biotech company that specializes in the research and development of targeted therapies for cancer treatment. The company focuses on developing drugs that target specific molecular pathways involved in cancer growth and survival. Aptose Biosciences utilizes innovative technologies and collaborations with academic institutions and industry partners to discover and develop promising treatments. Their goal is to provide effective therapies that improve patient outcomes and address unmet medical needs in oncology.

   Company Address: 251 Consumers Road, Suite 1105 Toronto 0 ON
   Company Phone Number: 479-9828   Stock Exchange / Ticker: NASDAQ APTO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Advances in TUS Clinical and Preclinical Findings at EHA 2024 A Promising Development for Aptose

Published Fri, Jun 14 2024 11:30 AM UTC

The European Hematology Association (EHA) 2024 Hybrid Congress witnessed a groundbreaking revelation in the field of hematological research, as Aptose Biosciences presented remarkable clinical and preclinical findings for their drug Tuspetinib (TUS). These findings hold significant implications for the company's future endeavors and the advancement of treatment options for p...


Aptose Biosciences Successfully Closes $4.43 Million Registered Direct Offering, Bolstering Financial Position and Demonstrating Biotech Industry Leadership

Published Mon, Jun 3 2024 8:30 PM UTC

Aptose Announces Successful Closure of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Following Remarkable Financial Performance
In a recent press release, Aptose Biosciences Inc. ('Aptose') proudly announced the completion of its highly successful registered direct offering, generating a substantial sum of $4.43 million. This achievemen...

Management Announcement

Aptose Biosciences: Navigating Challenges and Progress in the Healthcare Sector

Published Fri, May 31 2024 12:00 PM UTC

In recent news, Aptose Biosciences Inc, a leading biopharmaceutical company, has announced a registered direct offering priced at-the-market under Nasdaq rules, raising $4.43 million. This development comes amidst a decline in share prices, which plummeted by -30.63% during the second quarter of 2024. Furthermore, the company recorded a significant net loss of $49 ...

Financing Agreement

Aptose Therapeutics and Hanmi Pharmaceutical Join Forces in $12.4 Million Investment to Revolutionize Oncology Treatments

Published Fri, Jan 26 2024 1:00 PM UTC

Aptose Therapeutics Forges Strategic Partnership with Hanmi Pharmaceutical Alongside Successful Public Offering and Private Placement
In a significant move towards fortifying its position in the oncology market, Canadian biotechnology company Aptose Therapeutics recently announced the pricing of an $8.4 million public offering, combined with a concurrent $4 million priva...

Clinical Study

Tuspetinib: A Beacon of Hope for Relapsed/Refractory AML Patients - Promising Phase 1/2 Study Data Presented at the 2023 ASH Annual Meeting

Published Sat, Dec 9 2023 11:30 PM UTC

In a momentous breakthrough in the field of leukemia treatment, Aptose Biosciences' experimental drug Tuspetinib (TUS) has exhibited remarkable effectiveness in an ongoing Phase 1/2 study for patients with relapsed or refractory acute myeloid leukemia (AML). The impressive clinical data from this study was recently presented during the prestigious 2023 ASH Annual M...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com